Fulcrum Therapeutics (FULC) Interest Coverage Ratio (2018 - 2026)
Fulcrum Therapeutics' (FULC) quarterly Interest Coverage Ratio came in at 0.82 in Q1 2026, up 64.03% year-on-year from 0.5 in Q1 2025, and down 121.54% on a QoQ basis from 0.37 in Q4 2025.
Fulcrum Therapeutics (FULC) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 9 years of Interest Coverage Ratio data on file, last reported at 0.82 in Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 64.03% year-over-year to 0.82 in Q1 2026; TTM through Mar 2026 was 3.19, a 129.7% decrease from a year earlier, with the FY2025 full-year figure at 1.11, down 161.87% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 0.82, down from 0.37 in the prior quarter.
- Over the last five years, Interest Coverage Ratio for FULC reached as high as 4.25 in Q2 2024 and fell as low as 27.86 in Q2 2022.
- Historically, Interest Coverage Ratio has averaged 4.85 across 5 years, with a median of 0.89 in 2025.
- Across the five-year window, Interest Coverage Ratio slumped 3149.25% in 2022 and soared 143.8% in 2024, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.17 in 2022, then tumbled by 989.02% to 1.85 in 2023, then soared by 79.73% to 0.38 in 2024, then rose by 1.54% to 0.37 in 2025, then plunged by 121.54% to 0.82 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 0.82 in Q1 2026, 0.37 in Q4 2025, and 0.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Fulcrum Therapeutics | 286.57 Mn | 286.57 Mn | - | -0.82 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.82 |
| Dec 31, 2025 | -0.37 |
| Sep 30, 2025 | -0.50 |
| Jun 30, 2025 | -0.89 |
| Mar 31, 2025 | -2.28 |
| Dec 31, 2024 | -0.38 |
| Sep 30, 2024 | -19.38 |
| Jun 30, 2024 | 4.25 |
| Mar 31, 2024 | -0.85 |
| Dec 31, 2023 | -1.85 |
| Sep 30, 2023 | -2.14 |
| Jun 30, 2023 | -9.71 |
| Mar 31, 2023 | -10.24 |
| Dec 31, 2022 | -0.17 |
| Sep 30, 2022 | -8.92 |
| Jun 30, 2022 | -27.86 |
| Mar 31, 2022 | -0.39 |
| Dec 31, 2021 | -0.87 |
| Sep 30, 2021 | -0.27 |
| Jun 30, 2021 | -1.08 |